Ligand Pharms General CVR (LGNYZ) Stock Price, News & Analysis
Price Move History
- Daily moves over 5%
- 60 80 sessions, October 31, 2025 to October 29, 2026
- Largest daily move
- +150% close of April 24, 2026
Company Description
LGNYZ has declined 6.8% over the past week. The last closing price was $0.0440.
For FY2025, Ligand Pharms General CVR reported revenue of $268.1M with net income of $124.5M and diluted earnings per share of $6.13. The company operates at a net profit margin of 46.4%.
This page collects what Stock Titan holds for LGNYZ, including price data, SEC filings, insider trading activity, financial highlights, and short interest trends.
Stock Performance
Ligand Pharms General CVR (LGNYZ) closed at $0.0440 on October 29, 2026. Over the past week, the price has lost 6.8%.
LGNYZ Metrics & Rankings
Price returns through October 29, 2026. Ranking links may use different dates.
Latest News
SEC Filings
Ligand Pharms General CVR has filed 10 recent SEC filings, including 4 Form 4, 4 Form 144, 1 Form 10-Q, 1 Form 8-K. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all LGNYZ SEC filings →
Insider Radar
Insider selling at Ligand Pharms General CVR over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.
Financial Highlights
Ligand Pharms General CVR generated $268.1M in revenue in FY2025, operating income reached $41.0M (15.3% operating margin), and net income was $124.5M, reflecting a 46.4% net profit margin. Diluted earnings per share stood at $6.13. The company generated $49.4M in operating cash flow. The current ratio was 22.23, measuring current assets divided by current liabilities.
Upcoming Events
Short Interest History
Short interest in Ligand Pharms General CVR (LGNYZ) currently stands at 109.3 thousand shares, down 42.1% from the previous reporting period, representing 0.5% of the shares outstanding. Since November 2025, short interest has increased by 5269.6%.
Days to Cover History
Days to cover for Ligand Pharms General CVR (LGNYZ) currently stands at 1.0 days, down 99.9% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 1.0 to 1000.0 days.